Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease

Molecular Medicine

Volumn 5, Issue 9, 1999, Pages 569-582

  Barnum, S R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; COMPSTATIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; MACROPHAGE; MOLECULAR WEIGHT; MOUSE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; TREATMENT OUTCOME;

EID: 0033276595     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402070     Document Type: Review

References (129)

1. Acute phase proteins: Strategies for inhibition of complement activation in the treatment of neurodegenerative disorders
2. The role of complement in disorders of the nervous system
3. Up-regulated production and activation of the complement system in Alzheimer's disease brain
4. Complement anaphylatoxin receptor expression on neurons: New tricks for old receptors?
5. Novel complement therapeutics
6. Therapeutic inhibition of the complement system
7. Complement regulatory molecules: Application to therapy and transplantation
8. Complement in human diseases: Looking towards the 21st century
9. Xenotransplantation - State of the art - Update 1999
10. Inflammation of the brain in Alzheimer's disease: Implications for therapy
11. Experimental therapeutics of neurodegenerative disorders: Unmet needs
12. The U.S. economic and social costs of Alzheimer's disease revisited
13. The expression of complement regulatory proteins by adult human oligodendrocytes
14. The anaphylatoxin receptor for complement C3a is expressed by rat microglia and rat oligodendrocytes. Role in cell chemotaxis and cell activation
15. The role of complement in traumatic brain injury
16. Serum proteins bypass the blood-brain barrier for extracellular entry to the central nervous system
17. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury
18. Increased cerebrospinal fluid levels of complement components C3 and factor B discriminate bacterial from viral meningitis
19. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis
20. TNF-α-mediated expression of the receptor for anaphylatoxin C5a (C5aR) on neurons in experimental Listeria meningocephalitis
21. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and non-myeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis
22. Enhanced expression of chemotactic receptors in multiple sclerosis lesions
23. Expression of the receptor for the complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system
24. Kinetics of anaphylatoxin C5a receptor during experimental allergic encephalomyelitis
25. Human T-cells express the C5a receptor and are chemotattracted to C5a
26. The receptor for the C3a anaphylatoxin is expressed by glial cells and neurons in the normal and inflammed central nervous system
27. Experimental diffuse axonal injury induces enhanced neuronal C5a receptor expression in rats
28. Complement C1q and C4 mRNAs responses to lesioning in the rat brain
29. Transgenic models to study the actions of cytokines in the central nervous system
30. Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin 6 expression
31. Elevated complement C5a receptor expression on glial cells and neurons induced by the central nervous system production of interleukin-3 in transgenic mice
32. Structure, function and cellular expression of complement anaphylatoxin receptors
33. Anaphylatoxins and biological responses
34. In vitro and In vivo dependency of chemokine generation on C5a and TNF-alpha
35. Chemokines and chemokine receptors in CNS pathology
36. Cytokine actions in the central nervous system
37. Cytokine-induced inflammation in the central nervous system revisited
38. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation
39. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: Specific increase in interleukin-6 mRNA expression
40. Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement
41. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
42. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination
43. rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: Implications for B cell trafficking in secondary lymphoid tissues
44. Type 1 astrocytes and oligodendrocytetype 2 astrocyte glial progenitors migrate toward distinct molecules
45. Chemotaxis by a CNS macrophage, the microglia
46. C5a-induced expression of P-selectin in endothelial cells
47. Comparative effects of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells
48. C5a-dependent up-regulation in vivo of lung vascular P-selectin
49. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: The roles of P-selectin and platelet actuvating factor
50. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family
51. Complement activation by β-amyloid in Alzheimer disease
52. β-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain
53. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis
54. Complement interactions with amyloid b1-42: A nidus for inflammation in AD brains
55. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide
56. A mechanism of activation of the alternative pathway by the classical pathway: Protection of C3b from inactivation by covalent attachment to C4b
57. Mammalian lectins in activation and clearance mechanisms involving the complement system
58. The lectin pathway of the complement system
59. Complement-specific antibodies: Designing novel anti-inflammatories
60. Regulatory proteins of complement
61. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
62. Monclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs
63. A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex
64. GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells
65. Bacterial meningitis: Complement gene expression in the central nervous system
66. Structure-function relationships of leucocyte chemoattractant receptors
67. Chimeric receptors of the human C3a receptor and C5a receptor (CD88)
68. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristic of C3/C4 binding proteins
69. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding
70. Crystallization and preliminary X-ray diffraction analysis of a biologically active fragment of CD55
71. Complement receptors
72. Circulating soluble CR1 (CD35): Serum levels in diseases and evidence for its release by human leukocytes
73. Soluble human complement receptor typw 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
74. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis
75. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats
76. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
77. Results of a phase I trial of soluble complement receptor type 1 (TP10) in acute lung injury (ALI)
78. Soluble complement receptor type 1 inhibits complement-mediated host defense
79. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway
80. 2 chimeric complement inhibitor
81. x moieties
82. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules
83. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro
84. A slouble chimeric inhibitor complement inhibitory protein that possess both decay-accelerating and factor I cofactor activies
85. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein
86. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury
87. Development of transgenic mice with astrocyte-targeted expression of a soluble inhibitor of complement
88. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library
89. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation
90. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin
91. In vitro and in vivo inhibition of complement activity by a single chain Fv fragment recognizing human C5
92. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
93. Amelioration of lupus-like autoimmune disease in NXB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
94. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
95. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Role of the terminal complement components and inhibition by anti-C5 therapy
96. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
97. Genetically engineered antibodies and their application to brain delivery
98. Production of human antibody repertoires in transgenic mice
99. Crystallization of human complement component C5
100. Therapeutic approaches to the treatment of neuroinflammatory disease
101. 2-Amino-4H-3,1-benzoxazin-4-ones as inhibitors of Clr serine protease
102. Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement Clr protease
103. Structure of the catalytic region of human complement protease Cls: Study by chemical crosslinking and three-dimensional homology modeling
104. Structure and assembly of the catalytic region of human complement protease Clr: A three-dimensional model based on chemical cross-linking and homology modeling
105. Structure of human factor D, a complement system protein at 2.0 Å resolution
106. Structural basis of profactor D activation: From a highly flexible zymogen to a novel self-inhibiting serine protease, complement factor D
107. Complement enzymes
108. Induced fit activation mechanism of the exceptionally specific serine protease, complement factor D
109. Structure of 3,4-dichloroisocoumarin-inhibited factor D
110. Hexapeptide analogues of C5a anaphylatoxin reveal heterogeneous neutrophil agonism/antagonism
111. Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding
112. Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects
113. Development of C5a receptor antagonists. Differential loss of functional responses
114. Antagonistic peptides against human anaphylatoxin C5a
115. Novel C5a receptor antagonists regulate neutrophil functions in vitro and in vivo
116. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury
117. Synthetic antagonists of the anaphylatoxin C3a
118. Cyclic disulfide analogues of the complement component C3a: Synthesis and conformational investigations
119. Transporting therapeutics across the blood-brain barrier
120. Outwitting the blood-brain barrier for therpeutic purposes: Osmotic opening and other means
121. Chronic interstitia infusion of proteins to the primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging
122. Direct conventive delivery of macromolecules to the spinal cord
123. Brain drug delivery of small molecules using immunoliposomes
124. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design
125. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases
126. Engraftable human neural stem cells respond to developmental cues, replace neurons and express foreign genes
127. "Global" cell replacement is feasible via neural stem cell transplantation: Evidence from the dysmyelinated shiverer mouse brain